Back to News
Market Impact: 0.25
Amgen And AstraZeneca's IMDELLTRA-Imfinzi Combo Shows Survival Benefit In Phase 3 ES-SCLC Study
Source: Nasdaq
Healthcare & BiotechProduct Launches
Amgen reported an update on the Phase 3 DeLLphi-305 trial evaluating IMDELLTRA (tarlatamab-dlle) plus AstraZeneca's Imfinzi (durvalumab) against durvalumab alone as first-line maintenance therapy for patients with extensive-stage disease. The provided article text is truncated before disclosing trial efficacy, safety, or statistical results, limiting assessment of the commercial and investment implications.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
AMGN0.45
AZN0.10
More News
- Voyager: Maintaining A Strong Buy For Q4 PET Imaging Data AD And More
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- J&J prostate cancer drug shows promising tumor responses in early trial
- Scalpers offer Apple iPhone Duo buyers hundreds extra outside Beijing launch
- Apple’s $2,000 iPhone Duo Debuts With Limited Supply